Print

Syrrx, Inc. Researchers Report Atomic Structure Of Human HSD-1, An Important Target For The Potential Treatment Of Diabetes 
10/19/2005 5:12:05 PM

Syrrx Inc., a next generation structure-based drug discovery company, today reported the publication of the atomic structure of human 11(beta)-hydroxysteroid dehydrogenase type-1 (HSD-1). HSD-1 inhibitors are being investigated in clinical trials for the potential treatment of type II diabetes.
//-->